CoChat

A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C

Herson, Serge, Hentati, Faycal, Rigolet, Aude, Behin, Anthony, Romero, Norma B., Leturcq, France, Laforêt, Pascal, Maisonobe, Thierry, Amouri, Rim, Haddad, Hafedh, Audit, Muriel, Montus, Marie, Masurier, Carole, Gjata, Bernard, Georger, Christophe, Cheraï, Mustapha, Carlier, Pierre, Hogrel, Jean-Yves, Herson, Ariane, Allenbach, Yves, Lemoine, François M., Klatzmann, David, Sweeney, H. Lee, Mulligan, Richard C., Eymard, Bruno, Caizergues, Didier, Voït, Thomas, Benveniste, Olivier · 2012 · Brain
Cited by 91

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

γ-Sarcoglycanopathy or limb girdle muscular dystrophy type 2C is an untreatable disease caused by autosomal recessively inherited mutations of the γ-sarcoglycan gene. Nine non-ambulatory patients (two males, seven females, mean age 27 years; range 16-38 years) with del525T homozygous mutation of the γ-sarcoglycan gene and no γ-sarcoglycan immunostaining on muscle biopsy were divided into three equal groups to receive three escalating doses of an adeno-associated virus serotype 1 vector expressing the human γ-sarcoglycan gene under the control of the desmin promoter, by local injection into the extensor carpi radialis muscle. The first group received a single injection of 3 × 10(9) viral genomes in 100 µl, the second group received a single injection of 1.5 × 10(10) viral genomes in 100 µl, and the third group received three simultaneous 100-µl injections at the same site, delivering a total dose of 4.5 × 10(10) viral genomes. No serious adverse effects occurred during 6 months of follow-up. All nine patients became adeno-associated virus serotype 1 seropositive and one developed a cytotoxic response to the adeno-associated virus serotype 1 capsid. Thirty days later, immunohistochemical analysis of injected-muscle biopsy specimens showed γ-sarcoglycan expression in all three patients who received the highest dose (4.7-10.5% positively stained fibres), while real-time polymerase chain reaction detected γ-sarcoglycan messenger RNA. In one patient, γ-sarcoglycan protein was detected by western blot. For two other patients who received the low and intermediate doses, discrete levels of γ-sarcoglycan expression (<1% positively stained fibres) were also detectable. Expression of γ-sarcoglycan protein can be induced in patients with limb girdle muscular dystrophy type 2C by adeno-associated virus serotype 1 gene transfer, with no serious adverse effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awr342

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 91

Metadata

Authors
Herson, S., Hentati, F., Rigolet, A., Behin, A., Romero, N. B., Leturcq, F., Laforêt, P., Maisonobe, T., Amouri, R., Haddad, H., Audit, M., Montus, M., Masurier, C., Gjata, B., Georger, C., Cheraï, M., Carlier, P., Hogrel, J.-Y., Herson, A., Allenbach, Y., Lemoine, F. M., Klatzmann, D., Sweeney, H. L., Mulligan, R. C., Eymard, B., Caizergues, D., Voït, T., & Benveniste, O.
Venue
Brain
Published
2011-01-10
Volume
135
Issue
2
Pages
483-492
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2066619852
Cited by
91
References
15
FWCI
4.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. https://app.cochat.ai/papers/10.1093/brain/awr342
The paper
Herson, S., Hentati, F., Rigolet, A., Behin, A., Romero, N. B., Leturcq, F., Laforêt, P., Maisonobe, T., Amouri, R., Haddad, H., Audit, M., Montus, M., Masurier, C., Gjata, B., Georger, C., Cheraï, M., Carlier, P., Hogrel, J.-Y., Herson, A., . . . Benveniste, O. (2012). A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain. https://doi.org/10.1093/brain/awr342

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.